Case report study of the first five COVID-19 patients treated with remdesivir in France.
Adenosine Monophosphate
/ adverse effects
Adult
Aged
Aged, 80 and over
Alanine
/ adverse effects
Antiviral Agents
/ adverse effects
Betacoronavirus
/ drug effects
COVID-19
Coronavirus Infections
/ drug therapy
Female
France
Hospitalization
Humans
Male
Pandemics
Pneumonia, Viral
/ drug therapy
SARS-CoV-2
Viral Load
/ drug effects
Withholding Treatment
Antiviral therapy
Case reports
Remdesivir
SARS-CoV-2 viral load
Viral pneumonia
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
12
05
2020
revised:
26
06
2020
accepted:
26
06
2020
pubmed:
4
7
2020
medline:
22
9
2020
entrez:
4
7
2020
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the virus responsible for the coronavirus disease 2019 (COVID-19) outbreak worldwide. Data on treatment are scare and parallels have been made between SARS-CoV-2 and other coronaviruses. Remdesivir is a broad-spectrum antiviral with efficient in vitro activity against SARS-CoV-2. Evidence of clinical improvement in patients with severe COVID-19 treated with remdesivir is controversial. The aim of this study was to describe the clinical outcomes and virological monitoring of the first five COVID-19 patients admitted to the intensive care unit of Bichat-Claude Bernard University Hospital, Paris, France, for severe pneumonia related to SARS-CoV-2 and treated with remdesivir. Quantitative reverse transcription PCR was used to monitor SARS-CoV-2 in blood plasma and the lower and upper respiratory tract. Among the five patients treated, two needed mechanical ventilation and one needed high-flow cannula oxygen. A significant decrease in SARS-CoV-2 viral load in the upper respiratory tract was observed in most cases, but two patients died with active SARS-CoV-2 replication in the lower respiratory tract. Plasma samples were positive for SARS-CoV-2 in only one patient. Remdesivir was interrupted before the initialy planned duration in four patients, two because of alanine aminotransferase elevations (3 to 5 normal range) and two because of renal failure requiring renal replacement. This case series of five COVID-19 patients requiring intensive care unit treatment for respiratory distress and treated with remdesivir, highlights the complexity of remdesivir use in such critically ill patients.
Identifiants
pubmed: 32619764
pii: S1201-9712(20)30528-2
doi: 10.1016/j.ijid.2020.06.093
pmc: PMC7326458
pii:
doi:
Substances chimiques
Antiviral Agents
0
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Alanine
OF5P57N2ZX
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
290-293Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Lancet Infect Dis. 2006 Feb;6(2):67-9
pubmed: 16439323
Trials. 2020 Jan 3;21(1):8
pubmed: 31900204
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Med. 2020 Jun;26(6):861-868
pubmed: 32327757
Antimicrob Agents Chemother. 2020 Apr 21;64(5):
pubmed: 32152082
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204